Hipra plans to produce 400 million doses of its SARS-CoV-2 vaccine during 2022
After the emergence of the COVID-19 pandemic, as experts in vaccines for animal health, Hipra has taken a firm step towards human health with research and manufacture of a SARS-CoV-2 vaccine. The team that the multinational veterinary company has in its R&D center at the Barcelona Science Park – where part of the research for the design, generation and characterization of new vaccine antigens is carried out – is actively participating in the project.
The vaccine, HIPRA SARS-CoV-2, is a recombinant protein vaccine that has been designed to optimize its safety and induce a potent immune response that neutralizes the COVID-19 virus. It will be kept between 2 and 8º C, which will facilitate its logistics and distribution.
The vaccination strategy covers the various vaccination scenarios, effectiveness against different variants and the most likely and increasingly necessary booster doses. Clinical trials are expected to conclude successfully, so that production can begin in October of this same year, with the aim of launching commercialization in late 2021, subject to obtaining the appropriate authorizations.
According to current Hipra projections, 400 million doses are expected to be produced during 2022. By 2023, 1.2 billion doses could be reached.
The president of the Government of Spain, Pedro Sanchez, has visited the facilities of Hipra’s headquarters in Amer (Girona). He was accompanied by the Minister for Health, Carolina Darias, and by the Minister for Science and Innovation, Pedro Duque, as well as the Regional Health Councillor of Catalonia, Alba Vergés; the Mayor of the Local Council of Amer, María Rosa Vila; and the Chairman and CEO of the pharmaceutical company, David Nogareda.
During the visit, Pedro Sanchez met with the Company’s Management to follow at first hand the advances in research into the COVID-19 vaccine, whose clinical trials are expected to begin in June.
Hipra, with 50 years of experience in vaccine development, has a unique organizational model, which internally controls all processes in the value chain, generating unique know-how and making it a benchmark in vaccine research, production and marketing.
The Hipra project is supported by the Spanish Agency of Medicines and Health Products (Agencia Española de Medicamentos y Productos Sanitarios, AEMPS), as well as the Ministries of Health, Industry and Science and Innovation.
Hipra is currently also conducting a line of research in collaboration with Hospital Clinic in Barcelona for the development of a COVID-19 vaccine based on the mRNA of the virus. In addition, since the start of the pandemic, the pharmaceutical company made herself available to the health authorities by carrying out various altruistic actions such as processing PCR tests for health centres.